The Medical Publication and Scientific Communications Summit explores how communications and information professionals can convey crucial information to HCP decision-makers and non-expert audiences in a transparent, credible, and unbiased manner. The summit is organized at a crucial time when there is mistrust and misinformation in the medical industry. Industry thought leaders will offer their valuable advice on best practices for communicating information effectively to build trusted long-term relationships with patients. They will provide insights on ways of refining drug information to improve relationships with patients, which in turn will benefit patient outcomes. The event is hosted by Dynamic Global Events (“DGE”), a life science leader in organizing B2B events. Their portfolio caters to the informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries.  The program focuses on new publication methods that allow for communicating with patients in a simple language that is transparent and reliable. Important topics of discussion:

• Understanding patient expectations in digital space
• Predicting, understanding, and mitigating medical misinformation
• Uses for artificial intelligence in medical publishing
• The importance of PLS Summary in clinical research and medical literature
• Improving your publication partnerships
• Incorporating DE&I best practices into publication methods

The event is designed for medical device, pharma, and biotech professionals. This program will also benefit medical publication planning solutions and service providers and medical/science communications solutions and service providers. To learn more, please visit https://ibn.fm/tl71p.

• Of the revenue recorded in 2021 for the global music recording market, $18.7 billion belonged to major record labels; just under $7 billion was earned and pocketed by independent music artists
• Independent artists face problems with music production, distribution, and promotion, often losing rights to their music to the major labels, which provide the funding up front but enforce strict contracts
• Fan Pass Live 360-degree artist platform provides independent artists with the tools and support necessary to produce, distribute, and market their music without losing the rights

Independent artists face numerous obstacles in pursuing success in the music industry. With record labels controlling a majority of the revenue, it’s more than challenging for independent artists to find a real footing. According to IFPI, the global music recording market reported revenues of $25.9 billion in 2021. Of this global total, $18.7 billion belonged to the major record labels, meaning that just under $7 billion belonged to the independent music artist revenue (https://ibn.fm/QCYJ9). In addition, when compared to the 2020 numbers, it suggests that independent artist revenue is growing three times slower than that of the major labels. Friendable (OTC: FDBL), a mobile technology and marketing company focused on developing and identifying products, services, and brand opportunities, offers a 360-degree artist offering, free from labels, that answers the majority of the roadblocks encountered by independent artists who want to earn revenue but not at the cost of label control. For independent artists looking to turn their music from a hobby into a lifestyle, production, distribution, and marketing, are the three areas that matter. In most instances, record labels that sign an artist will give them money up front and then produce, distribute, and market the music – but with a major catch. When the record labels offer this handout to the artist, the artist loses the rights to the music and, in effect, become owned by the record label. When royalties are paid for the music, it often goes back to the label to “settle up” the amount given to the artist, and the artist is never in control of their music again. Friendable’s flagship offering, Fan Pass Live artist platform, in collaboration with the newly acquired Artist Republik and FeaturedX, changes how independent artists make their mark on the music industry while retaining 100% ownership of their music. Collectively, the Fan Pass Live 360-degree artist service offering provides independent artists access to produce, distribute, and market their music – all from their smartphones. The Fan Pass Live offering provides artists with:

• Music distribution and management
• Music production assistance
• Press release and Instagram promotion
• Digital storefront activation
• Artist marketplace for collaborations
• Merchandise, logo, and promotional design support
• Virtual concert booking and ticketing mobile streaming service
• Live streaming support
• Revenue from fan tips, monthly artist contests, merchandise, and ticket sales
• Access to fan data and performance analytics
• Monthly artist contests
• NFT development and Metaverse performances (coming soon)

The initial Fan Pass Live offering was released to the public in July 2020, during the pandemic, when the need for artists to have a virtual stage was high due to closed venues and performance spaces. The acquisition of Artist Republik and FeaturedX was finalized in January 2022 – completing Friendable’s “anti-label” artist offering. Having spent his life surrounded by independent music artists, Robert A. Rositano Jr., CEO and founder, saw an immediate need for artists to have control over the revenue from their music to support their pursuit of a career in the industry. His brother and co-founder, Dean Rositano, CTO and president, is also a musician, and together they have seen the struggle firsthand of artists working to make it in the industry. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• FingerMotion is a U.S.-based mobile communications technology services provider that is focused on the particular opportunities found in China’s world-leading population and enormous mobile user base
• The company has been building on collaborations with the nation’s largest telecommunications businesses, as shown by its recent work with state-owned China Mobile to build mobile services in the Fujian province
• FingerMotion has also been directing its big data operations through its Sapientus division to supply reinsurance agencies with tools to measure consumer risks while China’s credit and insurance risk standards are still in a nascent stage
• The company’s annual financial data reported in June showed big data revenue grew by 297 percent YOY, with 170 percent gains in telecommunications products and services also helping to drive overall revenues to a 37 percent increase

Russia’s war with Ukraine set the world’s economies on new paths this year amid supply chain disruptions rippling outward from the region and the crippling trade sanctions advanced internationally against Russia and entities that are still friendly to the largest country on earth by landmass. It is only one of the challenges globe-facing industries have had to deal with following a period that marked the rise of what widely has been described as “economic nationalism” — a tendency to push away from international trade in favor of locally produced products (https://ibn.fm/OvaV2). China, the largest country in the world by population, is no exception to the trend toward refocusing on market solutions, given the reliance of its enormous economy on globalization and foreign investment. While the nation has renewed efforts to strengthen its domestic economy, it remains steadfast in upholding international trade under what its leadership has termed “dual-circulation” policy (https://ibn.fm/o8ZfJ). U.S.-based evolving mobile technology services provider FingerMotion (NASDAQ: FNGR) serves China’s 1.4 billion-person mobile products user base as well as corporate big data clients, building a foreign involvement model that is powered by collaborations with China’s telco giants. That is exemplified most recently by efforts between FingerMotion subsidiary JiuGe and state-owned China Mobile to build up 5G wireless network enhancements for services such as SMS texting and MMS audio and video in China’s Fujian province, where some 30 million online subscribers are located (https://ibn.fm/sT5BF). Market analysts have forecast significant growth in China’s population’s mobile engagement from its already lofty levels, moving at a CAGR of 44.7 percent between 2020 and 2027 until it is valued at a quarter of the world’s expected $90.7 billion in market revenues by that point (https://ibn.fm/RRLBV). FingerMotion’s evolving big data capabilities are being brought to bear under its Sapientus division. FingerMotion’s current focus is on providing reinsurance companies a tool for measuring risk scoring and ways to simplify their policy underwriting processes, drawing on information from FingerMotion’s approximately 500,000 daily mobile payment and recharge service transactions. “With our data and our big data insights arm Sapientus we hope to fulfill our vision, which is to improve people’s lifestyle by understanding human behavior, by innovating new products, enhancing the products that already exist, and then hopefully with those consumer and understanding human behavior analytics we can improve lifestyle in general,” CEO Martin Shen said during a June corporate presentation at the 12th Annual LD Micro Invitational Conference in the Greater Los Angeles area’s Westlake Village (https://ibn.fm/e3NZL). The company’s big data revenues grew by 297 percent during the past year, according to a financial report also issued in June. The company reported its overall revenue grew by 37 percent YOY to $22.93 million, with big gains also noted in its telecommunications products and services, which increased by 170 percent (https://ibn.fm/ZB4TQ). For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• FuelPositive Corp. is a Canadian innovator putting the finishing touches on a demonstration system for the production of green ammonia and green hydrogen that will be a decentralized, non-carbon polluting source of fuel and fertilizer
• The company’s technological system will grant farmers new options in locally powering and fertilizing their farms without dependence on snarled supply chains that have continued to deteriorate through the ongoing pandemic and Russia-Ukraine war
• The 4-month-old Russian invasion of Ukraine and the resulting trade embargoes are having a significant impact on food and fertilizer shipments from the region known as the breadbasket of Europe and the world at large
• FuelPositive’s green solution also makes it an ideal means of providing energy to underserved, remote parts of the planet and a worthwhile alternative to carbon-intensive ammonia production

Russia’s war against Ukraine is entering its fifth month, continuing to disrupt agricultural commerce that supplies food to a large portion of the world’s population. While most of the impact is and will be felt between Europe and Africa, the Americas also are experiencing some economic base difficulties as a result of the conflict. The impact on food security will be felt globally in the coming months, as well. Clean energy solutions innovator FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is preparing to roll out its technologic solution to the difficulties resulting from global dependence on fertilizer and grain from the war-locked countries and centralized production and distribution modes. Its containerized, modular, scalable system for producing green, hydrogen-dense ammonia will be a means for farmers to generate fertilizer and fuel on their own farms. The United Nations has estimated that a large number of countries, including many in Latin America, receive up to 30 percent of their fertilizer supplies from Russia, which is subject to international trade blockades as a consequence of the nation’s aggression against Ukraine. The fertilizer shortages have begun producing significant increases in food prices, according to reporting by Truthout (https://ibn.fm/HvGUg). Similarly, grain and fertilizer shortages from the countries are affecting Canada’s agriculture, pushing wheat prices higher, according to a CBC report (https://ibn.fm/n00Vl). “And as commodity prices are high, farmers are going to try and produce as much as they possibly can,” Don Kabbes, general manager of Great Lakes Grain, told CBC. Great Lakes Grain markets grain for Ontario farmers, and although most wheat in Southern Ontario won’t be planted until the fall, Kabbes said farmers will step up “by using the latest technology and adding whatever they can to that to try and produce as much per acre as possible, and to try and fill that void and have good returns to their own farming operation.” FuelPositive’s first demonstration system is slated to be introduced on a farm in Manitoba this fall, with two additional demonstration systems due to roll out later. The system will be able to produce 500 liters per day (300 kilograms) of liquid anhydrous carbon-free ammonia, which is the approximate amount needed to fertilize a 2,000-acre farm, according to the company, but the output can be adjusted up or down based on the end use farm’s requirements (https://ibn.fm/99OsG). Green ammonia technology has been posited as a potential alternative to existing greenhouse gas-emitting fuel sources, particularly because of its capacity to also be converted to hydrogen. The agriculture industry is recognized as a major polluter, using about 80 percent of the traditional ammonia produced each year from carbon-intensive methods for fertilizer. “FuelPositive’s containerized green ammonia production systems are easy to transport to the end-user. The intention being that, with a decentralized system, FuelPositive can produce green ammonia exactly where and when it’s needed, and at a stable price,” said CEO Ian Clifford. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Approximately 200,000 commercial and industrial properties need retrofit each year to comply with the timeline for the established 2050 carbon goals
• As sales transactions increase (sales transactions totaled $809 billion in 2021) in the commercial real estate industry, there is a higher demand for clean energy solutions
• Correlate Infrastructure Partners Inc. offers a complete suite of proprietary clean energy assessment solutions and a finance platform to reduce site-specific energy consumption and deploy clean energy solutions for commercial real estate properties
• The renewable energy market is expected to reach $1,977.6 billion by 2030, growing at a CAGR of 8.7% over the forecast period

Environmental, social, and governance (“ESG”) norms have become an immediate focus for real estate assets, including monitoring and improving indoor air quality. However, one challenge the industry faces is building the ROI for technology beyond energy savings. While energy savings are easily quantified, smart building technology delivers numerous benefits, including reduced maintenance costs, improved comfort and productivity, and improved equipment performance. While most technological decisions are made at the executive level, it is critical to look at the whole model, specifically how it affects the end-user. In most circumstances, while skepticism of new technology implementation will exist, there is a much higher acceptance when the process is done using the end-user in mind. According to Real Capital Analytics, sales transactions for commercial real estate in 2021 totaled $809 billion. This was double the amount reported in 2020, with investors targeting more favorable asset classes in the wake of the pandemic. As this “boom” continues, the primary focus has been on warehouses and logistics properties (https://ibn.fm/uyC52). For the United States to reach the carbon goals established by 2050, approximately 200,000 commercial buildings will require retrofitting every year until then to be compliant. Correlate Infrastructure Partners (OTCQB: CIPI) offers a complete suite of proprietary clean energy assessment solutions for the commercial real estate industry. The company is currently at the forefront of creating industry-leading energy solutions and financing platforms for the commercial and industrial sectors. The company sees the need and market opportunity to reduce site-specific energy consumption and deploy clean energy solutions at scale. Correlate Infrastructure’s subsidiaries, Correlate and Solar Site Design, collectively share the mission that scaling distributed clean energy solutions is critical in mitigating climate change effects. Correlate was founded in 2015 and is a portfolio-scale development and finance platform that offers commercial and industrial sectors access to clean energy solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency solutions. Solar Site Design was founded in 2013 and is a US Department of Energy Sunshot Catalyst winner providing customer acquisition and project development tools for commercial solar energy. Solar Site Design’s platform gives commercial and industrial property owners access to the best price for implementing a commercial solar system. The company is leveraging growth opportunities emerging from the expanding global renewable energy market. In 2020, the sector was valued at $881.7 billion. By 2030, it is estimated that the value will increase to $1,977.6 billion, growing at a CAGR of 8.4%. Renewable energy sources are derived from natural resources and currently provide 7% of the world’s energy demand. Although more expensive than traditional fossil fuels, the exploration and implementation of renewable energy sources are necessary to combat the effects of climate change. More governments worldwide have begun focusing on promoting clean energy sources due to increased output efficiency, less pollution, and lower maintenance costs, fueling a surge in demand and in the market’s outlook (https://ibn.fm/8yvtq). For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The iGaming market is expected to reach $127 billion by 2027
• Golden Matrix Group provides turnkey gaming platforms giving iGaming operators access to over 10,000 games, state of the art loyalty and customer retention systems
• GMGI recently acquired and 80% stake in RKings, helping boost revenue 221% in Q1 to $8.48 million as it ventures into the Mexican markets and ESports industry

In 2021, the U.S. commercial gaming industry generated revenue of $53 billion, smashing the previous record set in 2019 at $43.65 billion. With new markets coming online, more records are almost certainly in the cards as evidenced by a Q1 record of $14.1 billion in nationwide revenue to start 2022. Although online gambling, or “iGaming” as it is colloquially called, is still not as popular as its land-based counterpart, the time has come, in the words of Betenemy.com, “for online casinos to be in the spotlights.” It’s anticipated that the iGaming market will reach $127 billion by 2027, growth that companies like Golden Matrix Group (NASDAQ: GMGI) intend to capitalize upon. The U.S. isn’t the only player at the table by any stretch of the imagination. Europe has a massive gambling population accounting for 49 percent of the global market, with estimates for 2022 gambling revenue around $100 billion. Online casinos are thriving in Europe, comprising 23 percent of the overall market. Asia Pacific, with its billions of inhabitants, is the world’s single biggest market, accounting for 32% of the $76.79 billion value of the global iGaming market in 2020. From its headquarters in Las Vegas, Nevada, Golden Matrix is a gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label B2B (business-to-business) gaming platforms for its international customers, primarily in the Asia Pacific region. The gaming IP includes tools for marketing, acquisition, retention, and monetization of users.  The platform is available in both desktop and mobile applications. Golden Matrix’s GM-X system, and newly launched GMX-Ag platform are a gold standard for the iGaming market, delivering access to 10,000+ games from over 25 leading game providers. More than 635 unique casino operations use Golden Matrix’s platform to serve more than 7 million registered players. The company made its entrance into the lucrative European markets with the acquisition of an 80% controlling interest in RKings Competitions Ltd. last November, with the option to acquire the remaining 20%. Based in England, RKings operates online competitions for players in the United Kingdom and Ireland where winners can take home exotic cars, vacations, electronics, and more. The acquisition of RKings was partially responsible for Golden Matrix revenue jumping 221% year-over-year in the first quarter to $8.48 million. As the online gaming industry continues to evolve, Golden Matrix is expanding horizontally and vertically. The company has submitted an application for a gaming license in Mexico where, once issued, it will roll-out its RKings iGaming tournament platform. Elsewhere, Golden Matrix is making its initial foray into the booming ESports market. The company is in an optimal position with its strong brand in Asia Pacific, effectively the birthplace of electronic sports and still the most robust marketplace in the world. Gambling on ESports has many unique sets of challenges to keep things fair and honest. To date, most major sports books only offer limited betting action on ESports and that is typically restricted to only games like the ever popular first-person CS: GO, and only during high-stakes tournaments where players are less tempted to potentially throw a game. Right now, Golden Matrix CEO Brian Goodman says his company is focusing on peer-to-peer Esports betting, another area that has been highly touted for its potential because bets can be customized and eliminate “the house” and setting the odds. Plus, peer-to-peer bets on Esports aren’t subject to as many regulatory restrictions as bona fide gambling operations, such as sports books and online casinos. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• QSAM Biosciences Inc. is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients
• CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical being evaluated for multiple indications
• CycloSam has been shown to cause significantly less buildup of long-lived radionuclidic impurities than prior FDA-approved drugs
• There is significant precedent that the radioisotope used in CycloSam, Samarium-153, is effective in treating bone cancer, as demonstrated in a published study conducted in over 500 patients using an older formulation of the drug
• There is also significant preliminary safety precedent for Samarium-153, as shown through the 2020 single patient IND and the super-therapeutic dose administered in that study
• QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio
• The company is led be an experienced management team with an extensive record of FDA approvals, big pharma partnerships and M&A transactions

QSAM Biosciences (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients. QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas. CycloSam(R) CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial. CycloSam(R) has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs. The indications for CycloSam(R) currently being evaluated by QSAM Biosciences include:

• Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam(R).
• Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam(R) to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
• Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (“IND”) study, an investigator concluded that high-dose CycloSam(R) can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union. Market Outlook Through its ongoing development of CycloSam(R), QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children. Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

• Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
• Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
• The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam(R) for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs. Management Team QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions. Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam(R), and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University. Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas. Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina. For more information, visit the company’s website at www.QSAMbio.com. NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM

• EverGen Infrastructure CEO, Chase Edgelow, was recently featured on IBN’s Bell2Bell podcast
• Edgelow elucidated on the origins of the company as well as its commercial objectives going forward
• EverGen recently purchased a 50% stake in an Ontario-based RNG project, with a cumulative production capacity of 1.7 million GJ per year

Chase Edgelow, Co-Founder and CEO of EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF), a British-Columbia based Natural Gas operator, was recently featured on the latest episode of the InvestorBrandNetwork’s Bell2Bell Podcast, with Edgelow seizing on the opportunity to expand on EverGen’s business model and operating markets (https://ibn.fm/s1tdx). Edgelow separately elaborated on EverGen’s recent announcement of its entry into definitive agreements with Northeast Renewables LP to acquire a 50 percent interest in a portfolio of Ontario-based renewable natural gas (“RNG”) development projects. Drawing from his background working at one of the world’s largest infrastructure asset managers, Edgelow initially expounded on the commercial philosophy underpinning his decision to co-found EverGen in 2020. “[In my previous role] I had an emphasis on finding assets that we could acquire or companies we could partner with where there was long-term contracted cash flow. In this environment, that stability of earnings is something that is highly sought-after,” Edgelow added. “[My co-founder and I] really wanted to find an opportunity to replicate some of that success in our own business, so we came up with EverGen”. Whilst setting out to create a stable, cash-generative business, Edgelow and co-founder, Mischa Zajtmann were simultaneously able to mold EverGen into a significant player within Canada’s renewable energy sector – helping drive the nation’s power grid’s transition towards a more sustainable, and carbon-free future. “We are a renewable natural gas energy company. We’re a developer, owner and operator of projects that take organic waste and convert that organic waste into renewable energy in the form of renewable natural gas (‘RNG’),” Edgelow said. “[Canadian utilities, like FortisBC] offer 20-year contracted offtakes to companies like ours to supply them with green energy, which provides a certainty for our business. Our business is then going out and building facilities that will take organic waste and convert it into RNG.” EverGen has sought to cater to the growing demand for renewable natural gas over the past two years, aggressively developing and expanding upon its supply capabilities. In addition to the company’s ownership of Fraser Valley Biogas, Western Canada’s first RNG facility which has been in continuous operation since 2011, EverGen also manages two composting and organic processing facilities, which will be expanded to combine anaerobic digesting and biogas upgrading technologies to produce RNG from the manure generated by local dairy farms as well as other organic waste. More recently, EverGen Infrastructure revealed that the company had purchased a 50% stake in a portfolio of renewable natural gas development projects in Ontario, Canada from Northeast Renewables (https://ibn.fm/afivq). The deal, which saw EverGen pay a gross cash consideration of $1.5 million, has a targeted cumulative production capacity of approximately 1.7 million gigajoules (“GJ”) per year, with projects set to come online between 2023 and 2024. Ultimately, EverGen expects the Ontario-based project to more than triple its RNG capacity to upwards of 1 million GJ per year. “The acquisition of Project Radius provides a foothold in Ontario – a new and strategic jurisdiction in which EverGen can continue to participate in the consolidation and growth of the RNG industry in the near-term, as well as benefit from project economics in line with or exceeding those we have seen with our initial projects,” Edgelow stated in relation to the stake purchase. “Ontario has an abundant amount of excess organic feedstock, and as a leader in the RNG industry, EverGen can develop the sustainable infrastructure that contributes to carbon-negative energy production and the greening of the province.” For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Daniel Brody, Eat Well’s Co-Founder and Director, has, since June 29, 2022, been buying shares in the company, totaling 8,430,625 as of June 29, 2022
• His purchases highlight his confidence in the company’s current trajectory and its commitment to creating shareholder value
• Eat Well maintains that its revenue guidance for its investee companies still stands at $90 million to $110 million for the 2022 fiscal year

The past year was monumental for Eat Well Investment Group (CSE: EWG) (OTC: EWGFF). Most notably, it marked the company’s market expansion following partnerships with vital retail companies in the United States and Canada, with customers in over 35 countries worldwide. In addition, the period saw the company grow its product offering in a move that aimed to grow its market share and create value for its shareholders. Going forward, Eat Well’s management has shared its plan to increase its production, specifically of its portfolio company Belle Pulses. Known for producing approximately 90,000 metric tons of protein in 2021, this company now seeks to increase its capacity to nearly 100,000 metric tons annually in Canada, with an additional 15,000 in the U.S (https://ibn.fm/rXUEA). “Shareholders should know that Belle is increasing its production capacity as it is our goal to help support the global food industry,” noted Mark Coles, Eat Well’s Chief Investment Officer (“CIO”). “We will continue to expand Belle’s operations and are looking forward to showing the world its ability to procure, process, and deliver proteins to the international marketplace,” he added. Such moves by Eat Well have elicited confidence from investors and shareholders, the most notable being the company’s Co-Founder and Director, Daniel Brody. Since June 20, 2022, Mr. Brody has been buying more shares in the company, with the most recent completed purchase dating June 29, 2022, equating to over 2,175,000 shares bought this month. Consequently, his shares currently stand at 8,430,625, and it is further projected that he will continue investing in the company (https://ibn.fm/cR2Tn). The plant-based foods market is projected to account for 7.7% of the global protein market by 2030 at over $162 billion. Bloomberg further notes that plant-based alternatives are here to stay and that consumption will only go up as time progresses. Eat Well understands this opportunity, hence its strategic positioning in the industry. Together, these factors point to the company’s strength and investment potential, as has been evidenced by Daniel Brody’s stock purchases. For 2022, Eat Well plans to scale up operations further for its portfolio companies. Belle Pulses’ management has projected an improved margin performance, with Amara continuing to bank on its 6,000 distribution points across North American retail to achieve its revenue targets (https://ibn.fm/3ngwj). To that effect, Eat Well maintains that its revenue guidance for its investee companies still stands at $90 million to $110 million for the 2022 fiscal year. Additionally, the company has cited that its bottom-line profitability of combined investments is projected to improve throughout the calendar year, showing how much value the company is creating for its shareholders and why it is worth investing in. For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

DGE’s 2nd Chief Patient Officer Summit being held on July 19-20, 2022 in Boston, MA is attended by industry leaders who offer valuable advice on the best practices for building trusted long-term relationships with patients, caregivers, and advocates. They offer their insights on cultivating a corporate culture dedicated to providing the best possible patient experience. Previous coverage of this topic has been applauded, where dignitaries dedicated to patient advocacy, engagement, education, and communication, all discussed how a patient’s opinion is critical and integrated into discovery research, clinical studies, and post-approval. The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing B2B events. The global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.  The in-person DGE summit will include keynotes, and panel discussions, and offers learning experiences from leaders for integrating patient preferences in order to create a more meaningful alliance. Important topics of discussion points include:

• Discuss and organize patient advisory boards, consultant programs, and patient counsels, to engage patients and note their preferences
• Embrace the global landscape of patient advocacy, and tune in to the culture, language, and local regulatory codes and guidelines
• Understand the legal aspects and compliance risks for relationships with patients, caregivers, and advocacy organizations
• Interact with patients to get their valuable feedback to improve alliances

Patient advocacy professionals will discuss how to put the patient first, from pre-clinical to post-approval. Panel discussions include reviewing opportunities for patient engagement, and global strategies for harmonious communication among health equity-focused patient organizations. The main emphasis of the event is to improve communication across the medical spectrum for an enhanced patient experience. To know more about the event, please visit https://ibn.fm/922Tg.